Sector News

Merck agrees to acquire Imago for $1.35bn

November 27, 2022
Life sciences

Merck (MSD outside North America) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences , through a subsidiary, for $36.00 per each share in cash or for a total equity price of nearly $1.35bn.

A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

The lead candidate of the company bomedemstat (IMG-7289) is an investigational, orally available inhibitor of lysine-specific demethylase 1 (LSD1).

At present, bomedemstat is being analysed in various Phase II clinical trials to treat myelofibrosis, essential thrombocythemia and polycythemia vera, apart from various other indications.

The Imago takeover will extend the growing haematology portfolio of Merck .

Merck president and CEO Robert Davis said: “We continue to invest in our pipeline with a focus on applying our unique capabilities to unlock the value of breakthrough science for the patients we serve.

“This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of haematology.”

As per the deal, the acquisition subsidiary of Merck will be merged into Imago following closing.

The acquisition is anticipated to conclude in the first quarter of next year.

Imago BioSciences founder and CEO Dr Hugh Rienhoff said: “This agreement leverages Merck’s industry-leading clinical development expertise to maximise the therapeutic potential of bomedemstat while providing important value for shareholders.”

In October this year, Merck reported worldwide sales of $15bn in the third quarter (Q3) of 2022 as against $13.15bn in the year-ago quarter, indicating a rise of 14%.

Source: pharmaceutical-technology.com

comments closed

Related News

March 15, 2024

Novo’s obesity superstar Wegovy wins FDA nod to cut cardio risks in key label expansion

Life sciences

Novo Nordisk’s fast-growing weight loss med Wegovy just added a new cardiovascular FDA approval to its label, likely enabling the med’s superstar status to reach new levels. The med is now the first weight loss treatment to score an FDA nod to reduce the risk of cardiovascular death, heart attack and stroke in adult patients with cardiovascular disease who have obesity or are overweight.

March 15, 2024

Galderma sets price range for supersized $2.6bn IPO in Europe

Life sciences

Galderma has announced a price range of CHF 49 to CHF 53 ($55.8 to $60.3) per share for floatation on the SIX Swiss Exchange. The Swiss skincare company, which revealed its intention to conduct an initial public offering (IPO) earlier in March, will have 40,453,467 new shares available. The offering also consists of 276,909 existing shares.

March 15, 2024

After transformation under new CEO, Leo Pharma touts innovation model and financial progress

Life sciences

Taking over as CEO for an aging company in dire financial straits and in need of a slim-down was a challenging assignment for Christophe Bourdon. But under Bourdon’s watch, Leo Pharma is taking steps toward a rebound. Last month, the 115-year-old Danish private company reported that it cut its operating costs by 14% in 2023 while increasing its revenues by 7%.

How can we help you?

We're easy to reach